On April 17, 2024, TORL Biotherapeutics LLC closed the transaction. The company has received a $300,000 in its second and final tranche, bringing total funding to $158,300,000 in the transaction. The transaction included participation from 52 investors pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
Pre-market 07:48:13 am | |||
44.64 USD | -0.47% | 44.98 | +0.77% |
11:37am | ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... | |
11:00am | Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.00% | 90.49B | |
+26.47% | 664B | |
+30.41% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+14.36% | 234B | |
+4.97% | 199B | |
-10.10% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors